» Articles » PMID: 31355319

Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD

Abstract

Objective: To develop a resource of systematically collected, longitudinal clinical data and biospecimens for assisting in the investigation into neuromyelitis optica spectrum disorder (NMOSD) epidemiology, pathogenesis, and treatment.

Methods: To illustrate its research-enabling purpose, epidemiologic patterns and disease phenotypes were assessed among enrolled subjects, including age at disease onset, annualized relapse rate (ARR), and time between the first and second attacks.

Results: As of December 2017, the Collaborative International Research in Clinical and Longitudinal Experience Study (CIRCLES) had enrolled more than 1,000 participants, of whom 77.5% of the NMOSD cases and 71.7% of the controls continue in active follow-up. Consanguineous relatives of patients with NMOSD represented 43.6% of the control cohort. Of the 599 active cases with complete data, 84% were female, and 76% were anti-AQP4 seropositive. The majority were white/Caucasian (52.6%), whereas blacks/African Americans accounted for 23.5%, Hispanics/Latinos 12.4%, and Asians accounted for 9.0%. The median age at disease onset was 38.4 years, with a median ARR of 0.5. Seropositive cases were older at disease onset, more likely to be black/African American or Hispanic/Latino, and more likely to be female.

Conclusions: Collectively, the CIRCLES experience to date demonstrates this study to be a useful and readily accessible resource to facilitate accelerating solutions for patients with NMOSD.

Citing Articles

Assessment of disability and disease burden in neuromyelitis optica spectrum disorders in the CIRCLES Cohort.

Gholizadeh S, Exuzides A, Sinnott J, Palmer C, Waltz M, Rose J Sci Rep. 2024; 14(1):26150.

PMID: 39477975 PMC: 11525583. DOI: 10.1038/s41598-024-75013-z.


Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder.

Vlahovic L, McDonald J, Hinman J, Tomczak A, Lock C, Palmer C Neurology. 2024; 102(1):e207965.

PMID: 38165361 PMC: 10834131. DOI: 10.1212/WNL.0000000000207965.


Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?.

Chu F, Shi M, Liu C, Zhu J Clin Exp Immunol. 2023; 213(3):363-370.

PMID: 37161978 PMC: 10570998. DOI: 10.1093/cei/uxad053.


The Role of Gut Dysbiosis and Potential Approaches to Target the Gut Microbiota in Multiple Sclerosis.

Ladakis D, Bhargava P CNS Drugs. 2023; 37(2):117-132.

PMID: 36690786 DOI: 10.1007/s40263-023-00986-w.


Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort.

Gholizadeh S, Exuzides A, Lewis K, Palmer C, Waltz M, Rose J J Neurol. 2022; 270(4):2048-2058.

PMID: 36565348 PMC: 10025181. DOI: 10.1007/s00415-022-11529-6.


References
1.
Wingerchuk D, Lennon V, Pittock S, Lucchinetti C, Weinshenker B . Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66(10):1485-9. DOI: 10.1212/01.wnl.0000216139.44259.74. View

2.
Cabre P, Gonzalez-Quevedo A, Lannuzel A, Bonnan M, Merle H, Olindo S . [Descriptive epidemiology of neuromyelitis optica in the Caribbean basin]. Rev Neurol (Paris). 2009; 165(8-9):676-83. DOI: 10.1016/j.neurol.2009.02.012. View

3.
Collongues N, Marignier R, Zephir H, Papeix C, Blanc F, Ritleng C . Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010; 74(9):736-42. DOI: 10.1212/WNL.0b013e3181d31e35. View

4.
Asgari N, Lillevang S, Skejoe H, Falah M, Stenager E, Kyvik K . A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011; 76(18):1589-95. PMC: 3269768. DOI: 10.1212/WNL.0b013e3182190f74. View

5.
Cossburn M, Tackley G, Baker K, Ingram G, Burtonwood M, Malik G . The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol. 2011; 19(4):655-9. DOI: 10.1111/j.1468-1331.2011.03529.x. View